Control of P-TEFb biogenesis and HIV transcription in primary T-cells

原代 T 细胞中 P-TEFb 生物发生和 HIV 转录的控制

基本信息

  • 批准号:
    10629307
  • 负责人:
  • 金额:
    $ 40.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Our understanding of HIV latency and persistence has been complicated by the small numbers of latently infected cells found in the circulation, the difficulty of obtaining comprehensive sets of tissue samples from patients, the lack of known phenotypic markers that can distinguish latently infected cells from uninfected ones, and limited information about the behavior of tissue reservoirs in vivo. Mechanistic studies, conducted primarily using cell line models of HIV latency, have shown that viral reactivation requires transactivation of epigenetically silenced proviruses by the viral Tat protein in complex with the host transcription elongation co-factors P-TEFb and the super elongation complex (SEC). Crucially for the study of HIV latency, additional P-TEFb control mechanisms exist in resting memory CD4+ T cells, where CycT1 protein levels are drastically reduced. We have also recently shown in primary T cells that CDK9 is present in an inactive state bound to Hsp90/Cdc37. Therefore, specific T-cell signaling pathways need to be activated in order to assemble a functional 7SK snRNP complex in primary cells. Using a refined highly reproducible primary cell model of HIV latency (the QUECEL model), we will address two key unsolved, but fundamental, questions on the transcriptional control of HIV latency: (1) How do T-cell signaling pathways regulate the assembly of P-TEFb, 7SK snRNP and the SEC in memory CD4+ T cells? (2) What Tat-dependent and independent T-cell molecular mechanisms allow for the exchange of P-TEFb from 7SK snRNP to the SEC and eventually to the latent HIV provirus? Our specific aims will investigate the regulation of the biogenesis and disassembly of 7SK snRNP by post- translational modifications and T-cell signaling pathways (Aim 1), apply fluorescence imaging of the spatiotemporal distribution and delivery of P-TEFb to the latent provirus (Aim 2) and define the biochemistry of the exchange of P-TEFb from 7SK snRNP during proviral reactivation (Aim 3). The key technological breakthrough, which distinguishes this work from virtually all previous studies of HIV transcription regulation is that we now have available reliable primary cell models for HIV latency and reactivation. Working with primary cells can be challenging since relatively limited numbers of cells are available. We therefore emphasize the use of imaging experiments and highly sensitive ChIP-Seq and RNA-Seq assays in the majority of our experiments. Defining the molecular and cell biological mechanisms leading to P-TEFb biogenesis and its transfer to the HIV promoter should provide the definitive identification of the pharmacological targets that is needed for the development of new and efficient classes of latency reversing agents.
我们对艾滋病毒潜伏期和持久性的理解由于数量少而变得复杂 在循环中发现的潜伏感染细胞,获得全面的成套的 组织样本,缺乏已知的表型标记,可以区分潜在的 受感染的细胞与未受感染的细胞之间的差异,以及关于组织储库行为的有限信息 in vivo.主要使用HIV潜伏期的细胞系模型进行的机制研究, 表明病毒的再活化需要表观遗传学沉默的前病毒的反式激活, 病毒达特蛋白与宿主转录延伸辅因子P-TEFb和超转录因子P-TEFb复合 延伸复合物(SEC)。对于HIV潜伏期的研究至关重要的是,额外的P-TEFb对照 机制存在于静息记忆CD 4 + T细胞中,其中CycT 1蛋白水平急剧升高。 降低我们最近还在原代T细胞中发现,CDK 9以非活性状态存在, 与Hsp 90/Cdc 37结合。因此,需要激活特定的T细胞信号通路, 以在原代细胞中组装功能性7SK snRNP复合物。使用精制的高重现性 艾滋病毒潜伏期的主要细胞模型(QUECEL模型),我们将解决两个关键未解决的问题,但 HIV潜伏期的转录控制的基本问题:(1)T细胞信号如何 通路调节记忆性CD 4 + T细胞中P-TEFb、7SK snRNP和SEC的组装? (2)什么样的Tat依赖性和非依赖性T细胞分子机制允许交换 P-TEFb从7SK snRNP到SEC并最终到潜伏的HIV前病毒?我们的具体 目的是研究7SK snRNP的生物合成和拆卸的调节, 翻译修饰和T细胞信号通路(目标1),应用荧光成像, P-TEFb向潜伏前病毒的时空分布和递送(目的2),并定义 在前病毒再活化过程中,7SK snRNP中P-TEFb交换的生物化学(目的 3)。关键的技术突破,使这项工作与以往几乎所有 研究HIV转录调控的一个重要原因是我们现在有了可靠的原代细胞模型 艾滋病毒潜伏期和再激活使用原代细胞可能具有挑战性,因为相对而言, 可用的单元数量有限。因此,我们强调使用成像实验 和高灵敏度的ChIP-Seq和RNA-Seq检测。限定 导致P-TEFb生物合成的分子和细胞生物学机制及其向 HIV启动子应该提供药理学靶点的确定性鉴定, 开发新型高效的延迟逆转代理所需的。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibition of the H3K27 demethylase UTX enhances the epigenetic silencing of HIV proviruses and induces HIV-1 DNA hypermethylation but fails to permanently block HIV reactivation.
  • DOI:
    10.1371/journal.ppat.1010014
  • 发表时间:
    2021-10
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Nguyen K;Dobrowolski C;Shukla M;Cho WK;Luttge B;Karn J
  • 通讯作者:
    Karn J
A Reliable Primary Cell Model for HIV Latency: The QUECEL (Quiescent Effector Cell Latency) Method.
  • DOI:
    10.1007/978-1-0716-1871-4_5
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Shukla;F. Kizito;U. Mbonye;Kien Nguyen;C. Dobrowolski;J. Karn
  • 通讯作者:
    M. Shukla;F. Kizito;U. Mbonye;Kien Nguyen;C. Dobrowolski;J. Karn
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JONATHAN KARN其他文献

JONATHAN KARN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JONATHAN KARN', 18)}}的其他基金

The role of RNA m6A modification in the regulation of HIV latency and reactivation
RNA m6A 修饰在调节 HIV 潜伏和再激活中的作用
  • 批准号:
    10600078
  • 财政年份:
    2022
  • 资助金额:
    $ 40.25万
  • 项目类别:
The role of RNA m6A modification in the regulation of HIV latency and reactivation
RNA m6A 修饰在调节 HIV 潜伏和再激活中的作用
  • 批准号:
    10461499
  • 财政年份:
    2022
  • 资助金额:
    $ 40.25万
  • 项目类别:
Research Support Core B: Primary Cell, Biomimetic, and iPSC-derived Cell Models
研究支持核心 B:原代细胞、仿生和 iPSC 衍生细胞模型
  • 批准号:
    10304584
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Research Support Core B: Primary Cell, Biomimetic, and iPSC-derived Cell Models
研究支持核心 B:原代细胞、仿生和 iPSC 衍生细胞模型
  • 批准号:
    10632094
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
New Inhibitors of HIV latency reactivation
HIV潜伏期再激活的新抑制剂
  • 批准号:
    10010720
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
New Inhibitors of HIV latency reactivation
HIV潜伏期再激活的新抑制剂
  • 批准号:
    10208701
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Control of P-TEFb biogenesis and HIV transcription in primary T-cells
原代 T 细胞中 P-TEFb 生物发生和 HIV 转录的控制
  • 批准号:
    10158438
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Regulation of HIV latency by microglial-neuronal interactions
小胶质细胞-神经元相互作用对 HIV 潜伏期的调节
  • 批准号:
    10220927
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Regulation of HIV latency by microglial-neuronal interactions
小胶质细胞-神经元相互作用对 HIV 潜伏期的调节
  • 批准号:
    10674037
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Control of P-TEFb biogenesis and HIV transcription in primary T-cells
原代 T 细胞中 P-TEFb 生物发生和 HIV 转录的控制
  • 批准号:
    10403547
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了